Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 7Colorectal Neoplasms 7Colonic Neoplasms 3Rectal Neoplasms 2Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Pancreatic Neoplasms 1Nasopharyngeal Carcinoma 1Lung Neoplasms 1Klatskin Tumor 1Head and Neck Neoplasms 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Epstein-Barr Virus Infections 1Cholangiocarcinoma 1Biliary Tract Neoplasms 1Bile Duct Neoplasms 1

Interventions

Gemcitabine 13Cisplatin 10Capecitabine 7pembrolizumab 3Oxaliplatin 3Leucovorin 3Chemotherapy, Adjuvant 3durvalumab 2Watchful Waiting 2Fluorouracil 2Dihematoporphyrin Ether 2zanidatamab 1becatecarin 1Tegafur 1Taxes 1Somatostatin 1S 1 (combination) 1Platinum 1Phototherapy 1Photochemotherapy 1Ondansetron 1Neoadjuvant Therapy 1Laser Therapy 1Irinotecan 1Folfox protocol 1Fentanyl 1Escitalopram 1Epirubicin 1Dexamethasone 1Chemoradiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Gallbladder Neoplasms × Tegafur × Clear all
NCT06109779 2026-03-04

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

AstraZeneca

Phase 3 Active not recruiting
757 enrolled
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡